Meeting
2024 ASCO Annual Meeting
Outpatient blinatumomab with digital monitoring in patients with measurable residual disease positive (MRD+) B-ALL in a phase 4 study.
Presenter
Michael Kenneth Keng, MD, FASCO
University of Virginia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT04506086
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 6544)
DOI
10.1200/JCO.2024.42.16_suppl.6544
Abstract #
6544
Poster Bd #
103
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2022 ASCO Gastrointestinal Cancers Symposium
Circulating tumor DNA-based molecular residual disease detection and recurrence monitoring in patients with advanced or metastatic anal squamous cell carcinoma.
Speaker: Georges Azzi, MD
Videos & Slides
2024 ASCO Breakthrough
Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study in Asia.
Speaker: Zhigang Li, MD, PhD
Videos & Slides
2024 ASCO Annual Meeting
ctDNA monitoring for breast cancer at high risk of recurrence: Interim analysis of JCOG1204A1.
Speaker: Yoichi Naito, MD
Videos & Slides
2024 ASCO Annual Meeting
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP).
Speaker: Benjamin Avi Derman, MD